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Steroid receptor coactivator 3 (SRC-3/AIB1/ACTR/NCoA-3) is a transcriptional coactivator for nuclear
receptors including vitamin D receptor (VDR). Growth hormone (GH) regulates insulin-like growth factor I
(IGF-I) expression, and IGF-I forms complexes with acid-labile subunit (ALS) and IGF-binding protein 3
(IGFBP-3) to maintain its circulating concentration and endocrine function. This study demonstrated that the
circulating IGF-I was significantly reduced in SRC-3/mice with the C57BL/6J background. However, SRC-3
deficiency affected neither GH nor ALS expression. The low IGF-I level in SRC-3/ mice was not due to the
failure of IGF-I mRNA and protein synthesis but was a consequence of rapid degradation. The rapid IGF-I
degradation was associated with drastically reduced IGFBP-3 levels. Because IGF-I and IGFBP-3 stabilize
each other, SRC-3/ mice were crossbred with the liver-specific transthyretin (TTR)-IGF-I transgenic mice
to assess the relationship between reduced IGF-I and IGFBP-3. In SRC-3//TTR-IGF-I mice, the IGF-I level
was significantly increased over that in SRC-3/mice, but the IGFBP-3 level failed to increase proportionally,
indicating that the low IGFBP-3 level is a responsible factor that limits the IGF-I level in SRC-3/ mice.
Furthermore, IGFBP-3 mRNA was reduced in SRC-3/ mice. The IGFBP-3 promoter activity induced by
vitamin D, through VDR, was diminished in SRC-3/ cells, suggesting an important role of SRC-3 in
VDR-mediated transactivation of the IGFBP-3 gene. In agreement with the role of SRC-3 in VDR function, the
expression of several VDR target genes was also reduced in SRC-3/mice. Therefore, SRC-3 maintains IGF-I
in the circulation through enhancing VDR-regulated IGFBP-3 expression.
Nuclear receptors are hormone-inducible transcription fac-
tors that require coactivators to mediate their transcriptional
activities (34). Most nuclear receptor coactivators exist in cells
at limiting concentrations, and their transcriptional activities
are regulated by various signaling pathway-triggered posttrans-
lational modifications (3, 32, 34). Accordingly, regulation of
coactivator concentrations and activities appears to be one of
the major means to control gene expression and metabolic
homeostasis regulated by hormones and their cognate recep-
tors. Conversely, coactivator dysfunction may cause a number
of developmental and physiological disorders and life-threat-
ening diseases (11, 34). In the p160 steroid receptor coactivator
(SRC) family (34), disruption of the SRC-1 gene in mice re-
sults in partial resistance to steroid and thyroid hormones (31,
36); disruption of SRC-2 (TIF2 or GRIP1) impairs both male
and female reproductive functions (5, 17); and disruption of
SRC-3 (AIB1, RAC3, p/CIP, ACTR, or TRAM-1) retards
somatic and mammary gland growth, reduces female repro-
ductive function, and suppresses oncogene- and carcinogen-
induced mammary tumorigenesis (9, 10, 30, 35). In addition,
SRC-3 is overexpressed in human breast cancers, and overex-
pression of SRC-3 in the mouse mammary epithelium is suf-
ficient to induce ductal carcinomas (1, 29). Therefore, studies
to understand the biological functions and molecular mecha-
nisms of nuclear receptor coactivators have been a recent focus
in the field of molecular endocrinology.
The p160 SRC coactivators interact with nuclear receptors
in a hormone-dependent manner and recruit protein acetyl-
transferases such as CBP, p300, and p/CAF and protein meth-
yltransferases such as CARM1 and PRMT1 to the promoter of
hormone-responsive genes. These SRC-recruited histone mod-
ification enzymes change the chromatin topology, facilitate
general transcription factor assembly, and potentiate transcrip-
tion (34). In cultured cells, overexpression of each SRC mem-
ber increases most nuclear receptor-mediated transactivation,
suggesting that each SRC can serve as a coactivator for mul-
tiple nuclear receptors (34). This notion is further supported
by our findings showing partial redundancy of function be-
tween SRC-1 and SRC-2 in promoting Purkinje cell develop-
ment in the cerebellum, spermatogenesis in the testis, and
postnatal viability (17, 21). On the other hand, the distinct
phenotypes observed in mice lacking SRC-1, SRC-2, or SRC-3
indicate that each SRC member has a specific biological func-
tion, presumably due to its preference for specific transcription
factors and/or its temporal and spatial expression patterns (6,
7, 34, 35, 39). One of the unique phenotypes observed in
SRC-3/ mice is the significantly reduced insulin-like growth
factor I (IGF-I) level in the circulation (35). However, the
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mechanisms responsible for SRC-3 control of IGF-I circulating
levels remain to be characterized.
IGF-I, as a growth hormone (GH) target, plays an essential
role in regulation of postnatal somatic growth. Inactivation of
the IGF-I gene in mice severely impairs somatic growth after
birth (8, 15, 24, 28). In the circulation, most IGF-I associates
with IGF-binding protein 3 (IGFBP-3) and acid-labile subunit
(ALS) to form ternary complexes, which remarkably increases
IGF-I and IGFBP-3 stabilities in the circulation and efficiently
maintains the reservoir of IGF-I and its endocrine function (8,
28). It has been demonstrated that overexpression of IGFBP-3
increases plasma IGF-I in transgenic mice (20). Conversely,
IGF-I reduction decreases circulating IGFBP-3 without affect-
ing its mRNA expression (37). These studies indicate that
IGF-I and IGFBP-3 depend on each other for stability. These
associated changes between IGF-I and IGFBP-3 make it dif-
ficult to assess which one is the initiative factor if both are
reduced in the circulation.
The liver is the principal organ that produces circulating
IGF-I and ALS (8, 28). ALS is exclusively expressed in the
liver, and its expression is dependent on GH stimulation. GH
also directly stimulates IGF-I mRNA expression in the liver
and other tissues. IGFBP-3 is more broadly expressed in the
kidney, liver, and other organs (8, 28). The mechanism for
transcriptional regulation of IGFBP-3 is less clear, although
some studies suggest that GH may indirectly regulate IGFBP-3
expression through enhancing IGF-I production (4, 26). Sev-
eral studies have demonstrated that the IGFBP-3 promoter
contains a functional vitamin D response element (VDRE)
and that vitamin D-activated vitamin D receptor (VDR) binds
to the VDRE and significantly enhances the transcriptional
activity of the IGFBP-3 promoter (18, 23). This raises the
possibility that SRC-3 serves as a coactivator of VDR to reg-
ulate IGFBP-3 expression.
In this study, we show that genetic ablation of SRC-3 in mice
results in a significant decrease in circulating IGF-I levels. The
IGF-I decrease is caused not by GH and IGF-I expression but
by a rapid IGF-I clearance in the circulation. The rapid IGF-I
degradation in SRC-3/ mice is associated with a drastic
reduction of serum IGFBP-3 levels that cannot be restored by
transgenic IGF-I compensation. Furthermore, disruption of
SRC-3 in mice decreases the expression of IGFBP-3 and sev-
eral other known VDR target genes. SRC-3-deficient cells in
culture are also unable to support vitamin D-induced IGFBP-3
promoter activity. These compelling findings demonstrate that
SRC-3 plays an important role in maintenance of normal se-
rum IGF-I levels through regulation of IGFBP-3 expression.
MATERIALS AND METHODS
Mice. Animal protocols were approved by the Animal Care and Use Commit-
tee for Baylor College of Medicine. SRC-3/ mice were initially generated in a
129SvEv/C57BL/6J genetic background as described previously (35). To reduce
possible complications of different strain backgrounds, we backcrossed these
mice with C57BL/6J mice for six generations. The transthyretin (TTR)-IGF-I-
transgenic mice were generated in the C57BL/6J strain background as described
previously (13). Double-heterozygous mice were produced by breeding the back-
crossed male SRC-3/ mice with the female TTR-IGF-I mice. Bigenic mice
with combinatorial genotypes of SRC-3 and TTR-IGF-I were generated by one
more generation of breeding. TTR-IGF-I mice used for all experiments were
heterozygous to the IGF-I transgene. Mouse genotypes were analyzed by PCR
using genomic DNA isolated from ear tips after proteinase K digestion and
allele-specific primer pairs as described previously (13, 35). For growth analysis,
body weights of wild-type (WT) and SRC-3/ mice were measured weekly from
postnatal day 3 (P3) to P90. The same groups of mice were weighed again at P180
and P365.
Mouse IGF-I and GH assay. Blood samples were collected by periorbital
puncture, and serum was isolated after the blood was clotted at 4°C. The con-
centration of total IGF-I in the serum was measured by using a radioimmuno-
assay (RIA) kit for rat IGF-I (Diagnostic Systems Laboratories, Webster, TX) as
described previously (35). For measuring IGF-I levels in tissues, mice were
anesthetized with avertin (2.5%, 0.3 ml/mouse) and their blood circulating sys-
tem was perfused with 20 ml phosphate-buffered saline (PBS) from the left
ventricle to the right ventricle. Tissues were dissected, frozen immediately in
liquid nitrogen, and stored in a 80°C freezer. Frozen tissues were pulverized
under liquid nitrogen and then collected into cold Eppendorf tubes. Each 100 mg
of tissue powder was mixed with 0.5 ml of 1 M acetic acid, incubated on ice for
2 h, and then centrifuged at 600  g for 10 min. Supernatant was saved, and the
precipitate was extracted one more time. The combined supernatants were dried
under a speed vacuum, and the dried samples were reconstituted in 200 l of 50
mM Tris-HCl (pH 7.8) for each 100 mg of tissue. The IGF-I concentration in the
reconstituted samples was assayed as described above and normalized to tissue
weight. The concentration of mouse GH in the serum was measured by using a
mouse/rat GH enzyme-linked immunosorbent assay kit (RPA551; Amersham
Biosciences, Piscataway, NJ) with its primary antibody replaced by the rabbit
anti-recombinant GH immunoglobulin G made in the Parlow laboratory
(AFP5672099; 1:100,000 dilution in PBS with 3% bovine serum albumin [BSA]).
Analysis of IGF-I stability in vivo. Mice were injected with recombinant
human IGF-I (hIGF-I) (0.25 g/g of body weight, intraperitoneally) after 30
l of blood was collected from their tails. After hIGF-I injection, mice were
bled over a time course. The concentration of hIGF-I in the serum was
measured by using the hIGF-I-specific RIA kit (Diagnostic Systems Labora-
tories, Webster, TX).
Immunoblotting assay. Mouse pituitaries were individually collected and ho-
mogenized in lysis buffer containing 50 mM Tris-HCl (pH 7.4), 0.1% sodium
dodecyl sulfate (SDS), 2 M phenylmethylsulfonyl fluoride, and 10 g/ml leu-
peptin. The samples were sonicated and centrifuged. Pituitary lysate containing
2 g of protein was separated by SDS-polyacrylamide gel electrophoresis
(PAGE) and transferred to a nitrocellulose membrane. The blot was probed with
the rabbit anti-recombinant GH antibody produced in the Parlow laboratory and
developed by using the Enhanced Chemiluminescence kit (Amersham Bio-
sciences, Piscataway, NJ).
Ligand blot assay. IGF-binding proteins were assayed by ligand blotting as
performed previously (13). Briefly, 0.5 l of serum was mixed with nonreducing
sample buffer for SDS-PAGE and boiled for 5 min. The sample was separated by
running a 10% SDS-PAGE minigel at 100 V and blotted onto a nitrocellulose
membrane. The membrane was washed with saline, incubated in saline contain-
ing 3% NP-40 at 4°C for 30 min, blocked with saline containing 1% RIA-grade
BSA (A-7888; Sigma, St. Louis, MO) at 4°C for 2 h, and washed with 0.1%
Tween 20 in saline at 4°C for 10 min. The washed membrane was incubated with
5 105 cpm of 125I-hIGF-I in a sealed bag with 5 ml of saline containing 1% BSA
and 0.1% Tween 20 overnight at 4°C. After incubation the membrane was
washed twice with 0.1% Tween 20 in saline and then three times in saline before
being exposed to X-ray film for 2 days.
RPA. An RNase protection assay (RPA) was carried out by using the RPA III
kit (Ambion, Austin, TX). Total RNA was prepared from liver and kidney by
using Trizol reagent (Invitrogen, Carlsbad, CA) and hybridized with 32P-labeled
riboprobes. The riboprobes for protecting IGF-I, ALS, IGFBP-3, and cyclophilin
A mRNAs were described previously (13). The probe-protected samples were
separated by running a 6% acrylamide denatured gel. The gels were dried and
exposed to X-ray films at 80°C.
qPCR. RNA samples were prepared from mouse livers and kidneys and mouse
embryonic fibroblasts (MEFs). The relative concentrations of IGFBP-3, SRC-1,
SRC-2, and SRC-3 mRNAs were measured by quantitative TaqMan real-time
reverse transcription-PCR (qPCR) using the One-Step Master Mix reagent (Ap-
plied Biosystems, Foster City, CA) as described previously (21). The relative
concentrations of calbindin D9K, calbindin 28K, CYP3A11, CYP24, P21, and
type IIa Na-Pi cotransporter (NPT2) mRNAs were measured by qPCR using
gene-specific primer pairs and matched universal mouse probe sets (Roche
Applied Science, Mannheim, Germany). Specifically, the 5-AGTTCCCCAGC
CTCCTGA and the 3-AACTTCTCCATCGCCATTCTT primers and probe 17
were used for calbindin D9K, the 5-GACGGAAGTGGTTACCTGGA and the
3-ATTTCCGGTGATAGCTCCAA primers and probe 17 were used for calbi-
ndin 28K, the 5-TCAATATCTAAGGATGATGAATGGAA and the 3-TCA
ATGACAGGGAACATCTCC primers and probe 56 were used for CYP3A11,
the 5-AACTGTACGCTGCTGTCACG and the 3-AATCCACATCAAGCTG
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TTTGC primers and probe 78 were used for CYP24, the 5-TCCACAGCGAT
ATCCAGACA and the 3-GGCACACTTTGCTCCTGTG primers and probe 9
were used for P21, and the 5-CGAGGGTATAAAGAAGAGGGTCT and the
3-GGCACCCACAATGAGTCCT primers and probe 60 were used for NPT2.
All data were normalized to the 18S RNA concentration of the same sample.
Transfection assay. Stable cultures of WT and SRC-3/ MEFs were main-
tained in Dulbecco modified Eagle medium with 10% fetal bovine serum. For
transient-transfection assays, MEFs were plated in six-well plates overnight and
transfected with pGL3-basic, pGL3-BP3(1901/55), or pGL3-BP3(3590/
55) plasmid containing the luciferase reporter by using the Fugene 6 transfec-
tion reagent (Roche Applied Science, Indianapolis, IN). All cells also were
cotransfected with the pRSV-Gal expression plasmid, which served as a control
for transfection efficiency. Transfected cells were treated with 108 M 1,25-
dihyroxy-vitamin D3 [1,25-(OH)2D3] or 107 M 9-cis-retinoic acid (9-cis-RA) for
24 h. Cell lysates were prepared, and the luciferase activity was measured with a
luciferase assay kit (Promega, Madison, WI). The -galactosidase activity in the
same amount of cell lysate also was measured. Relative luciferase units were
normalized to the -galactosidase activity.
RESULTS
SRC-3 deficiency causes growth retardation and low IGF-I
levels without affecting GH synthesis and secretion. We have
previously shown that SRC-3/ young mice with a mixed
129SvEv and C57BL/6J strain background exhibited postnatal
growth retardation that was accompanied by a significant re-
duction in serum IGF-I levels (35). In this study, these mice
were backcrossed with C57BL/6J mice for six generations to
reduce possible phenotypic influence from a mixed strain back-
ground. WT and SRC-3/ mice for experiments were pro-
duced from the sixth generation of heterozygous breeding
pairs. The average body weights between the backcrossed male
SRC-3/ and WT mice were similar up to P28, but male
SRC-3/ mice were significantly lighter than male WT mice
after P35 (Fig. 1A). The average body weight of female SRC-
3/ mice was also significantly lower than that of female WT
mice after P21 (data not shown). The lower body weight of
SRC-3/ mice was in accord with their reduced organ weight.
The average weights of brain, pituitary, heart, liver, and kidney
in 8-week-old SRC-3/ mice were statistically lower than
those of the same organs in age-matched WT mice (Table 1).
In addition, SRC-3/ mice displayed a shorter body length
than age-matched WT mice (Table 1). The serum IGF-I levels
in the backcrossed SRC-3/ mice were significantly reduced
as examined at P40 and P180 compared with age-matched WT
mice (Fig. 1B). These results indicate that SRC-3 also regu-
lates somatic growth and circulating IGF-I levels in mice with
the backcrossed C57BL/6J strain background.
Since 75% of IGF-I in the circulation is produced in the liver
in response to GH stimulation (37), we examined GH levels in
the pituitary and serum. Immunoblotting analysis of samples
from multiple mice revealed that GH protein levels in the
pituitary extracts were comparable between WT and SRC-3/
mice when samples with equal amount of protein were ana-
FIG. 1. Body weight comparison and levels of IGF-I and GH in WT and SRC-3/ mice. (A) Body weight comparison between male WT (/)
and SRC-3/ (/) mice over the period of 1 year (52 weeks). The average body weight of SRC-3/ mice (n  8) was similar to that of WT
mice (n  8) before the age of 5 weeks (P 	 0.05, unpaired t test) but was significantly decreased below that of WT mice over 5 weeks of age
(P 
 0.01, unpaired t test). (B) Measurement of serum IGF-I levels in WT and SRC-3/ male mice at ages of 40 days (10 mice for each group)
and 180 days (seven mice for each group). The serum IGF-I levels were statistically higher in WT mice than in SRC-3/ mice (P
 0.01 and 0.001
by t test at ages of 40 and 180 days, respectively). (C) Immunoblotting analysis of the pituitary extracts (2 g of protein per lane) prepared from
two mice for each group by using a GH-specific antibody (upper panel), showing comparable GH protein levels in the pituitaries of WT and
SRC-3/ mice. The lower panel shows a protein band revealed by R-250 Coomassie blue staining of the gel with identical sample loading.
(D) Measurement of GH levels in male WT and SRC-3/ mice. For each mouse, serum samples were prepared at three different time points (see
Materials and Methods). There was no significant difference in the serum GH levels between WT (n  10) and SRC-3/ (n  10) mice.
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lyzed (Fig. 1C). Because of the pulsatile fashion of GH secre-
tion, we performed the following procedure to obtain reliable
measurement of serum GH levels. Blood samples were col-
lected from male adult SRC-3/ and age-matched WT mice
at 8 a.m. on experimental day 1, 3 p.m. on day 14, and 10 p.m.
on day 28, so that animals could recover after each bleeding.
GH levels in individual samples were measured, and the aver-
age GH level for each mouse was calculated from the three
samples collected at the three time points. Our assay demon-
strated that the average serum GH levels in SRC-3/ mice
were similar to those in WT mice (Fig. 1D). These results
indicate that disruption of SRC-3 in mice does not affect GH
synthesis and secretion. Therefore, the growth deficit and
lower IGF-I levels in SRC-3/ mice are not caused by GH
deficiency.
The serum IGF-I reduction in SRC-3/ mice is not caused
by lower IGF-I mRNA expression but by rapid IGF-I degra-
dation. To examine whether the lower serum IGF-I levels in
SRC-3/ mice were caused by a reduction of IGF-I gene
transcription, we measured the IGF-I mRNA levels by RPA.
Interestingly, IGF-I mRNA was comparably expressed in WT
and SRC-3/ mice in all organs examined, including liver,
testis, muscle, kidney, and brain (Fig. 2A and data not shown).
To address whether SRC-3 deficiency would affect IGF-I pro-
tein synthesis, we measured the IGF-I protein levels in differ-
ent tissues after the mouse circulation system was thoroughly
flushed with PBS. Our assay revealed that the amounts of
IGF-I protein in the liver, skeletal muscle, heart, kidney, and
testis were similar in WT and SRC-3/ mice (Fig. 2B). Again,
we repeatedly observed a significant reduction of IGF-I con-
centration in the serum (Fig. 2B). These results indicate that
inactivation of SRC-3 does not affect the transcription of IGF-I
mRNA and the translation of IGF-I protein.
The above results logically prompted us to check IGF-I
stability after its secretion into the blood circulation. In this
experiment, hIGF-I was injected into WT and SRC-3/ mice
and the hIGF-I degradation profiles in mice were monitored
TABLE 1. Organ weights and body lengths of SRC-3/ micea
Parameter
Mean value  SD for mouse
type
Significance of
difference between
mouse types
(unpaired t test)bWT KO
Wt (mg) of organ
Brain 447  26 393  23 VS
Pituitary 1.50  0.28 1.02  0.10 VS
Heart 103  10 85  6 VS
Liver 1,024  98 772  72 VS
Kidney 292  35 221  40 S
Spleen 68  8 70  30 NS
Body length (cm) 8.88  0.27 8.32  0.29 S
a Data were obtained from 8-week-old male WT (n  8) and SRC-3-knockout
(KO) (n  5) mice.
b VS, very significant (P 
 0.01); S, significant (P 
 0.05); NS, not significant
(P 	 0.05).
FIG. 2. IGF-I expression and stability in SRC-3/ mice. (A) RPAs showing comparable expression levels of IGF-I mRNA in liver, testis, and
skeletal muscle of WT and SRC-3/ mice. Five micrograms of liver RNA and 15-g testis and muscle RNA samples prepared from two mice of
each genotype group were analyzed. Yeast RNA (Y-RNA) was used as a negative control. The protected cyclophilin A (Cycl.) served as a control
for RNA input. P-IGF-1, IGF-I probe; P-Cycl., cyclophilin A probe. (B) IGF-I levels in different tissues. A significantly lower level of IGF-I was
observed only in the serum of SRC-3/ mice compared with WT mice. Six mice were assayed for each genotype group. , P 
 0.01 by unpaired
t test. (C) Degradation of human IGF-I in WT and SRC-3/ mice. Recombinant hIGF-I was administrated at zero time, and serum levels of
hIGF-I were measured before and after hIGF-I administration at indicated time points. Six mice were assayed for each genotype group. Note the
much faster degradation of hIGF-I in SRC-3/ mice than in WT mice. , P 
 0.01 by unpaired t test.
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by measuring the serum concentrations of hIGF-I using an
RIA kit that specifically detects hIGF-I but not the endoge-
nous mouse IGF-I (Fig. 2C). In WT mice, the serum hIGF-I
concentration reached the maximum level in 10 min after in-
jection. This maximum value was maintained for 40 min, and it
dropped to 50% at 70 min after injection. About 10% of the
injected IGF-I was maintained up to 5 h in the circulation of
WT mice (Fig. 2C). In contrast, the injected hIGF-I was much
more rapidly degraded in SRC-3/ mice than in WT mice. In
SRC-3/ mice, a decrease in serum hIGF-I was first observed
at 40 min after injection and an 80% decrease in serum hIGF-I
was found at 70 min after injection. By 100 min, the injected
hIGF-I became undetectable in SRC-3/ mice (Fig. 2C).
These results indicate that SRC-3 plays a critical role in IGF-I
stabilization in the circulation and that disruption of SRC-3
significantly accelerates IGF-I degradation.
SRC-3 deficiency drastically decreases serum IGFBP-3 con-
centration. Since IGF-binding proteins play essential roles in
stabilizing IGF-I in the circulation (8, 28), we performed ligand
blot analysis using the 125I-labeled IGF-I to measure the levels
of IGF-binding proteins in the circulation. In the serum of WT
and SRC-3/ mice, abundant IGFBP-3 proteins and low lev-
els of IGFBP-2 and IGFBP-4 were clearly detected (Fig. 3). In
the serum of SRC-3/ mice, the levels of IGFBP-2 and
IGFBP-4 were unaltered compared with those of WT and
SRC-3/ mice. However, the levels of IGFBP-3 in the serum
of SRC-3/ mice were drastically reduced compared with the
levels of IGFBP-3 in the serum of WT and SRC-3/ mice
(Fig. 3). These results indicate that SRC-3 deficiency causes a
significant reduction of serum IGFBP-3 concentration, which
is associated with the accelerated degradation of IGF-I in
SRC-3/ mice.
Compensation of the circulating IGF-I with a liver-specific
transgene in SRC-3/ mice is unable to restore serum
IGFBP-3 levels. It has been shown that liver-specific IGF-I-
deficient mice have a 75% reduction in serum IGF-I levels,
which is associated with a drastic decrease in serum IGFBP-3
levels (38). To assess whether the low IGFBP-3 levels in SRC-
3/ mice were caused by IGF-I reduction in these mice, we
investigated whether restoration of the circulating IGF-I levels
in SRC-3/ mice by expression of IGF-I from a liver-specific
TTR-IGF-I transgene would rescue IGFBP-3 levels. In the
TTR-IGF-I mouse line generated in our laboratory, the IGF-I
transgene was driven by the liver-specific TTR enhancer/pro-
moter and its liver-specific expression resulted in a 50% in-
crease in biologically active IGF-I in the circulation (13). We
then crossed TTR-IGF-I mice with SRC-3/ mice and pro-
duced WT/TTR-IGF-I and SRC-3//TTR-IGF-I bigenic
mice for experimental analysis (Fig. 4A). RPA was performed
to examine the expression of the TTR-IGF-I transgene in these
bigenic mice. The transgenic IGF-I mRNA was abundantly
and comparably expressed in the livers of WT/TTR-IGF-I and
SRC-3//TTR-IGF-I mice, and the transgene expression had
no effect on the expression of the endogenous IGF-I gene in
these mice compared with WT and SRC-3/ mice (Fig. 4B).
RIA was performed to measure the serum levels of IGF-I. The
serum IGF-I levels were increased about 50% in WT/TTR-
IGF-I mice compared with WT mice (P 
 0.001, one-way
analysis of variance [ANOVA]). The IGF-I levels in
SRC-3//TTR-IGF-I mice were also significantly elevated
compared with SRC-3/ mice (P
 0.001, one-way ANOVA),
and it reached the average IGF-I level in WT mice. However,
the average IGF-I level in SRC-3//TTR-IGF-I mice was
much lower than that in WT/TTR-IGF-I mice (P 
 0.001,
one-way ANOVA) (Fig. 4C). These results demonstrate that
overexpression of the liver-specific TTR-IGF-I transgene can
only partially elevate the circulating IGF-I levels in SRC-3//
TTR-IGF-I mice, suggesting that IGF-I in SRC-3//TTR-IGF-I
mice is still less stable than IGF-I in WT/TTR-IGF-I mice.
Next, we performed ligand blot assays to examine whether
an up-regulation of IGF-I levels by the TTR-IGF-I transgene
would also elevate the IGFBP-3 levels in the circulation of
SRC-3//TTR-IGF-I mice. Our analysis showed that serum
IGFBP-3 levels were similar in WT and WT/TTR-IGF-I mice
(Fig. 4D), suggesting that elevation of circulating IGF-I in WT
mice does not further increase the concentration of circula-
ting IGFBP-3. Importantly, the serum IGFBP-3 levels in
SRC-3//TTR-IGF-I mice were much lower than those in
WT and WT/TTR-IGF-I mice, and they showed only a small
increase compared with SRC-3/ mice (Fig. 4D), indicating
that compensation of IGF-I levels in the circulation system of
SRC-3/ mice does not efficiently rescue the serum IGFBP-3
levels.
SRC-3 deficiency affects IGFBP-3 mRNA expression. Since
the low serum IGFBP-3 level was not a consequence of low
serum IGF-I level in SRC-3/ mice, we next investigated how
SRC-3 deficiency affects IGFBP-3 mRNA expression.
IGFBP-3 is expressed in multiple tissues, and the mechanisms
regulating IGFBP-3 expression in vivo are currently less well
understood. RPAs using total RNA samples prepared from the
kidneys of multiple WT and SRC-3/ mice revealed that the
expression levels of IGFBP-3 mRNA were significantly re-
duced (Fig. 5A). Because IGFBP-3 is expressed only in the
nonparenchymal cells in the liver (28) and could not be easily
detected by RPA, we performed qPCR, a more sensitive assay,
to measure the expression levels of IGFBP-3 in the liver. Our
assay showed that the expression levels of IGFBP-3 in the liver
were reduced about 50% in SRC-3/ mice compared with
WT mice (Fig. 5B). These results indicate that SRC-3 is re-
quired for IGFBP-3 expression in liver and kidney.
Since the circulating IGF-I forms ternary complexes with
both IGFBP-3 and ALS, we also examined ALS expression.
ALS is regulated by GH and solely expressed in the liver.
RPAs with a riboprobe complementary to ALS mRNA re-
vealed that ALS mRNA was comparably expressed in the livers
FIG. 3. Severely reduced serum IGFBP-3 protein in SRC-3/
mice. Serum protein was separated by nonreducing SDS-PAGE and
blotted onto a nitrocellulose membrane. IGF-binding proteins were
detected by incubating the membrane with 125I-labeled IGF-I. Note
that IGFBP-3 was significantly reduced but that IGFBP-2 and
IGFBP-4 were unchanged in SRC-3/ mice (n  3) compared with
WT and SRC-3/ mice (n  3).
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of WT and SRC-3/ mice (Fig. 5C), suggesting that SRC-3 is
not required for ALS gene expression.
SRC-3 enhances vitamin D-induced IGFBP-3 promoter ac-
tivity. Recently, a functional VDRE has been identified in the
IGFBP-3 promoter region (23). Since SRC-3 interacts with
VDR and potentiates its transcriptional activity (22), we as-
sessed the role of SRC-3 in VDR-dependent activation of the
IGFBP-3 promoter by cellular transfection assays in the pres-
ence or absence of SRC-3. For this purpose, we developed
MEFs from WT and SRC-3/ mouse embryos and immor-
talized these cells by serial passages as described previously
(33). Among members of the p160 SRC family, SRC-1 and
SRC-2 were comparably expressed in WT and SRC-3/
MEFs as measured by qPCR (Fig. 6A); SRC-3 was expressed
in WT MEFs, but it was absent in SRC-3/ MEFs as expected
(Fig. 6A). In transfectional assays using these cells, we utilized
FIG. 4. Generation and analysis of SRC-3//TTR-IGF-I bigenic mice. (A) Breeding strategy for generation of the bigenic mice by crossing
SRC-3/ mice with the TTR-IGF-I transgenic mice. (B) Expression of the endogenous and transgenic IGF-I mRNA in the liver of WT (/),
WT/TTR-IGF-I (), SRC-3/ (/), and SRC-3//TTR-IGF-I () mice. RPA was performed with 15 g of liver RNA isolated from two mice
of each genotype group and with the probe (IGF-I/T) that could detect the endogenous (partial sequence protection) and the transgenic
(full-length protection) IGF-I mRNA. (C) Serum IGF-I levels. Serum samples were prepared from age-matched WT (n  20), WT/TTR-IGF-I
(n  23), SRC-3/ (n  20), and SRC-3//TTR-IGF-I (n  12) mice. Non-Tg, mice negative for the TTR-IGF-I transgene. One-way ANOVA
indicates no significant difference (P 	 0.05) in IGF-I levels between WT (/) and SRC-3//TTR-IGF-I mice; all other comparisons between
the two groups showed significant differences (P 
 0.01). (D) Levels of IGFBP-3 in serum in WT (/), WT/TTR-IGF-I (), SRC-3/ (/),
and SRC-3//TTR-IGF-I () mice were analyzed by ligand blotting using 125I-labeled IGF-I. Samples from two mice of each genotype group were
assayed. Note that the IGFBP-3 levels in SRC-3//TTR-IGF-I and SRC-3/ mice were significantly lower than those in WT/TTR-IGF-I and WT
mice.
FIG. 5. Analysis of IGFBP-3 and ALS expression. (A) Reduced IGFBP-3 expression in the kidney of SRC-3/ mice. RPA was performed with
15 g of RNA isolated from the kidneys of three WT and three SRC-3/ mice. Yeast RNA (Y-RNA) was used as a negative control. The
protected cyclophilin (Cycl.) RNA served as a loading control of total RNA input. (B) Reduced IGFBP-3 expression in the liver of SRC-3/ mice.
qPCR measurement of relative IGFBP-3 mRNA levels in the livers of WT and SRC-3/ mice. The data were normalized to 18S RNA
measurements of the same samples and are presented as averages  standard deviations. RNA samples from six mice for each genotype group
were measured in triplicate. The average concentration in SRC-3/ liver is significantly lower than that in WT liver (P 
 0.01, unpaired t test).
(C) ALS mRNA expression in the liver of WT (/) and SRC-3/ (/) mice. RPA was performed with 15 g of RNA isolated from the livers
of three WT and three SRC-3/ mice.
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the pGL3-basic vector containing only the luciferase coding
sequence, the pGL3-BP3(1901/55) vector containing the
promoter region of the IGFBP-3 gene from bp 1901 to 55
and the pGL3-BP3(3590/55) vector containing the pro-
moter region of the IGFBP-3 gene from bp3590 to55. The
functional VDRE mapped recently was located in the pro-
moter region of the IGFBP-3 gene from bp 3590 to 1901
(Fig. 6B) (23). Transfection of the pGL3-basic and the pGL3-
BP3(1901/55) vectors into WT and SRC-3/ MEFs pro-
duced minimal luciferase activity regardless of the absence or
presence of 1,25-(OH)2D3 and 9-cis-RA for activation of VDR
and its heterodimerization partner retinoid X receptor (RXR)
(Fig. 6C), suggesting that the promoter region of the IGFBP-3
gene from 1901 to 55 is not regulated by vitamin D and
9-cis-RA in WT and SRC-3/ MEFs. In contrast, transfection
of the pGL3-BP3(3590/55) vector into WT MEFs resulted
in an increase in luciferase activity, indicating that the
BP3(3590/55) region has promoter activity in these cells.
More importantly, the promoter activity of the BP3(3590/
55) region was significantly potentiated in WT MEFs by
either vitamin D treatment or vitamin D and 9-cis-RA treat-
ment, suggesting that the ligand-activated VDR/RXR strongly
enhances the promoter activity of the BP3(3590/55) region
containing a known functional VDRE (Fig. 6C). Nevertheless,
transfection of the pGL3-BP3(3590/55) reporter into SRC-
3/ MEFs failed to exert an appreciable promoter activity,
and treatment of these transfected SRC-3/ MEFs with vita-
min D or vitamin D plus 9-cis-RA was unable to increase the
luciferase production. Therefore, the vitamin D-induced tran-
scriptional activity of VDR on the IGFBP-3 promoter is se-
verely compromised in MEFs lacking SRC-3. Collectively,
these results suggest that SRC-3 is required for vitamin D-
induced activation of the IGFBP-3 promoter.
Furthermore, if decreased IGFBP-3 expression was a result
of reduced VDR function, the expression of other VDR target
genes might also be affected. To test this possibility, we per-
formed qPCR and measured the expression levels of several
known VDR target genes, including calbindin D9K, calbindin
28K, CYP3A11, CYP24, P21, and NPT2 in the kidney (12, 16,
25, 40, 42). These assays revealed that the expression levels of
calbindin D9K, calbindin 28K, P21, and NPT2 were signifi-
cantly reduced in SRC-3/ mice compared with WT mice.
CYP24 expression showed no significant change (Fig. 6D).
CYP3A11 expression was undetectable in the kidneys of both
WT and SRC-3/ mice (data not shown). These results indi-
cate that SRC-3 deficiency selectively decreases the expression
of certain VDR target genes.
FIG. 6. SRC-3 is required for vitamin D-induced activation of the IGFBP-3 promoter and VDR target gene expression. (A) Real-time reverse
transcription-PCR measurement of SRC-1, SRC-2, and SRC-3 mRNA levels in WT and SRC-3/ (KO) MEFs. The data were normalized to 18S RNA
levels in the same samples and are presented as averages standard deviations. (B) Luciferase (Luc) reporter DNA constructs. VDRE, a VDRE located
in the 5 regulatory region of the IGFBP-3 gene. (C) Transfection analysis. WT (/) and SRC-3/ (/) MEFs were transfected with pGL3-basic,
pGL3-BP3(1901/55), or pGL3-BP3(3590/55) luciferase reporter plasmid and treated with vitamin D (VD) or with VD and 9-cis-RA. Luciferase
activity was normalized to the cotransfected -galactosidase activity, expression of which was directed by a constitutively active cytomegalovirus promoter.
The bar graph was generated by using data from one of the three experiments. Each experiment was done in triplicate. Statistical calculation was
performed based on all three experiments with nine repeats. , P
 0.01 by one-way ANOVA. (D) Relative expression levels of VDR target genes. The
relative levels of calbindin D9K (D9K), calbindin 28K (28K), CYP24, P21, and NPT2 mRNAs were measured by qPCR using RNA samples prepared
from kidneys of WT and SRC-3/-knockout (KO) mice (n  5). Data were normalized to 18S RNA. The average relative levels of gene expression in
WT mice were set as 1 unit.  and , P 
 0.05 and P 
 0.001, respectively, by unpaired t test.
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DISCUSSION
The major goal of this study is to understand the mecha-
nisms responsible for SRC-3 controlling the serum IGF-I con-
centration. We have shown that genetic ablation of SRC-3
causes a significant reduction of circulating IGF-I in back-
crossed C57BL/6J SRC-3/ mice, which is associated with
postnatal growth retardation, indicating that the role of SRC-3
in regulation of circulating IGF-I and somatic growth in
C57BL/6J mice is consistent with that observed in 129SvEv/
C57BL/6J mice (35). Interestingly, SRC-3 deficiency does not
significantly alter GH synthesis and secretion as well as IGF-I
mRNA expression and protein production in tissues, suggest-
ing that SRC-3 is not required for normal production of GH
and GH-regulated IGF-I expression. We also have shown that
the expression of ALS, a well-defined GH target gene in the
liver, is not affected in SRC-3/ mice. Thus, the low IGF-I
levels in SRC-3/ mice are due to neither GH deficiency nor
IGF-I expression.
Instead, the low IGF-I levels in SRC-3/ mice are associ-
ated with rapid IGF-I degradation and remarkably reduced
IGFBP-3 levels in the circulation. Since previous studies have
demonstrated that IGF-I and IGFBP-3 can stabilize each other
and reduction of either one of them will decrease the level of
the other one in the circulation (20, 37), it is important to
understand which alteration, the low IGF-I or the low
IGFBP-3, is the initial change and which one of them is a
secondary effect. We have addressed this question by generat-
ing WT/TTR-IGF-I and SRC-3//TTR-IGF-I bigenic mice.
In these transgenic mice, the IGF-I transgene is expressed only
in the liver (13). Our data have demonstrated that expression
of TTR-IGF-I in the liver efficiently elevates serum IGF-I in
both WT/TTR-IGF-I and SRC-3//TTR-IGF-I mice. The av-
erage serum IGF-I level in SRC-3//TTR-IGF-I mice is sim-
ilar to that in nontransgenic WT mice. However, the serum
IGF-I level in SRC-3//TTR-IGF-I mice is still much lower
than that in WT/TTR-IGF-I mice. Further analysis has re-
vealed that compensation of IGF-I levels in SRC-3//TTR-
IGF-I mice only slightly increases serum IGFBP-3 levels and is
unable to restore IGFBP-3 to normal levels in these mice. The
small increase of IGFBP-3 may be attributed to the positive
effect of elevated IGF-I on IGFBP-3 stability (20, 37). Since
the serum IGFBP-3 levels are quite low in both SRC-3/ and
SRC-3//TTR-IGF-I mice, these findings indicate that the
low IGFBP-3 level is not a consequence but a cause of the low
IGF-I level in SRC-3/ mice.
After IGFBP-3 was identified as a limiting factor for IGF-I
stability in SRC-3/ mice, the expression of IGFBP-3 mRNA
was further found to be decreased in all examined tissues
including liver and kidney of SRC-3/ mice. These results
suggest that SRC-3 is required for IGFBP-3 expression. Re-
cently, it has been demonstrated that the 5 regulatory region
of the IGFBP-3 gene contains a functional VDRE between
3296 and 3282. VDR showed strong binding to this VDRE
both in vivo and under cell-free conditions in the presence of
1,25-(OH)2D3. More importantly, the 1,25-(OH)2D3-induced
VDR recruitment to the VDRE site of the IGFBP-3 promoter
significantly stimulated IGFBP-3 promoter activity and IGFBP-3
mRNA expression in LNCaP cells and other types of cells (18,
23). On the other hand, SRC-3 has been shown to be a transcrip-
tional coactivator for VDR; SRC-3 interacts with VDR in a li-
gand-dependent manner and enhances 1,25-(OH)2D3-induced
and VDR-dependent transcription in keratinocytes (22). Based
on these studies, we reasoned that SRC-3 might serve as a coac-
tivator for VDR to regulate IGFBP-3 expression. Indeed, we
found that the VDR/RXR-mediated transcriptional activity of
the IGFBP-3 promoter is dependent on the mapped VDRE and
the presence of SRC-3 in MEFs. These results indicate that
SRC-3 is required for 1,25-(OH)2D3-induced IGFBP-3 promoter
activity and that this promoter activity is dependent on VDR
binding to the VDRE in the IGFBP-3 promoter region.
In agreement with the SRC-3 coactivator activity in VDR-
mediated IGFBP-3 expression, the expression of four out of
five previously known VDR target genes in the kidney was
found to be significantly reduced in SRC-3/ mice. Since
these genes are not solely regulated by VDR and SRC-3, it is
not surprising to see differential effects of SRC-3 deficiency on
the expression of different vitamin D-responsive genes. Over-
all, our data support the notion that SRC-3 is an in vivo
coactivator for VDR. In addition, a previous study has shown
that VDR-knockout mice were smaller and had 29% lower
IGF-I levels in serum than did WT mice when fed a normal
diet (27). In the future, it will be interesting to find out if the
reduced IGF-I levels in VDR-knockout mice are also a con-
sequence of reduced IGFBP-3 expression.
Although this study has demonstrated the activation func-
tions of SRC-3 and VDR for the IGFBP-3 expression, other
nuclear receptors might also be involved in SRC-3-regulated
IGFBP-3 expression. It has been shown that activation of the
RA receptor  (RAR) by 9-cis-RA can induce IGFBP-3
expression in cultured cells and that the IGFBP-3 promoter
contains active DR-8 RA response elements (2). Since SRC-3
is also a putative coactivator of RAR (19), it cannot be ex-
cluded that a partially decreased RAR function might also
contribute to the reduced IGFBP-3 expression in SRC-3/
mice. Furthermore, it has also been shown that the estrogen
antagonist ICI 182780 could induce IGFBP-3 expression in
breast cancer cells, suggesting that the function of estrogen
receptor (ER) is to suppress IGFBP-3 expression. Since
IGFBP-3 is reduced in SRC-3/ mice, where the estrogen
level and ER function are partially reduced (35, 41), the al-
tered estrogen and ER function should not be responsible for
the decrease in IGFBP-3 expression in SRC-3/ mice. In
addition, IGFBP-3 was found to interact with RXR in the cell
nucleus (14). However, it is unclear if SRC-3 is involved in the
modulation of RXR activity by IGFBP-3.
Although the three members of the SRC family are homol-
ogous to each other (34), SRC-1 and SRC-2 do not have the
same role as SRC-3 in regulating somatic growth and IGF-I
levels in the circulation. SRC-1- and SRC-2-knockout mice
showed normal or nearly normal somatic growth and normal
IGF-I and IGFBP-3 levels (5, 36). The present study also
showed that although both SRC-1 and SRC-2 were comparably
expressed in WT and SRC-3/ MEFs, the vitamin D-stimu-
lated IGFBP-3 promoter activity was still compromised in
SRC-3/ MEFs. Therefore, only SRC-3 in the SRC family
plays a major role in regulating IGFBP-3 expression for main-
tenance of the circulating concentration and endocrine func-
tion of IGF-I. However, additional studies are required for
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understanding the underlying mechanisms governing the spec-
ificity of SRC-3 for IGFBP-3 expression in vivo.
Taken together, our findings have revealed a novel role for
SRC-3 in regulation of IGFBP-3 and IGF-I concentrations in the
circulation. SRC-3 serves as an in vivo transcriptional coactivator
for VDR, and it enhances IGFBP-3 mRNA expression. Inactiva-
tion of SRC-3 causes down-regulation of IGFBP-3 mRNA ex-
pression, leading to a reduction of IGFBP-3 protein levels in the
circulation. Consequently, the low IGFBP-3 levels shorten the
half-life of IGF-I and cause a rapid degradation of IGF-I, result-
ing in low IGF-I levels in the circulation. Therefore, it appears
that SRC-3 maintains normal circulating IGF-I levels and its
endocrine function by regulating IGFBP-3 expression.
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